Cancer Center Member Publications and Abstracts Site

Latticegrid
Powered by LatticeGrid

Brady Lee Stein, MD, MHSEdit profile     Publications     Word cloud      
Visualizations: Radial1     Radial2     Spring     Wheel     Chord     Tree     Awards     Studies    
Graph of all data     Reports: Awards     Studies     MeSH: similarities graph    
Academic TitleAssistant Professor
DepartmentMedicine, Hematology Oncology Division; Feinberg School of Medicine
AffiliationsHematologic Malignancies (Member)
CampusChicago
AddressGALTER 676 N St Clair St #850 CH HNMH
Email
DescriptionDr. Stein is interested in the clinical investigation and clinical epidemiology of the classical Myeloproliferative Neoplasms. He has focused on the correlation between molecular and genetic abnormalities and clinical phenotype in these disorders, as well as the influence of gender on disease manifestations. He currently serves as the institutional PI for an international consortium (MPD-RC) as well as the institutional PI for JAK-inhibitor studies in patients with Myelofibrosis and Polycythemia Vera. Dr. Stein is collaborating with Dr. Crispino's lab, evaluating new druggable targets in the MPN, along with Dr. Platanias, who is studying interferon signaling in the MPN. Finally, Dr. Stein is working with Dr. Kwaan to focus on the role of tissue-factor and PAI-1 bearing microparticles and their role in thrombosis in patients with MPN.
InterestsMyeloproliferative Neoplasms, Clinical Epidemiology, Clinical Investigation
PubMed IDs
Show ➲

Publications (25)

no pagination
Publications
Kaur, S.; Kroczynska, B.; Sharma, B.; Sassano, A.; Arslan, A. D.; Majchrzak-Kita, B.; Stein, B. L.; McMahon, B.; Altman, J. K.; Su, B.; Calogero, R. A.; Fish, E. N.; Platanias, L. C. Critical roles for Rictor/Sin1 complexes in IFN-dependent gene transcription and generation of antiproliferative responses.J Biol Chem (2014) In process. 24469448; PMC3945321; 10.1074/jbc.M113.537852
Tabarroki, A.; Visconte, V.; Rogers, H. J.; Sekeres, M. A.; Samaras, C.; Lichtin, A.; Duong, H. K.; Englehaupt, R.; Cinalli, T.; Dodd, K.; Desamito, J.; Rouphail, B.; Altman, J. K.; Stein, B. L.; Tiu, R. V. Clinical Experiences with Ruxolitinib in Symptomatic MPN Patients with Chronic Kidney Disease.Leuk Lymphoma (2014) 55:213-216. 23607256; 10.3109/10428194.2013.797086
Greenberg, P. L.; Attar, E.; Bennett, J. M.; Bloomfield, C. D.; Borate, U.; De Castro, C. M.; Deeg, H. J.; Frankfurt, O.; Gaensler, K.; Garcia-Manero, G.; Gore, S. D.; Head, D.; Komrokji, R.; Maness, L. J.; Millenson, M.; O'Donnell, M. R.; Shami, P. J.; Stein, B. L.; Stone, R. M.; Thompson, J. E.; Westervelt, P.; Wheeler, B.; Shead, D. A.; Naganuma, M. Myelodysplastic syndromes: clinical practice guidelines in oncology.J Natl Compr Canc Netw (2013) 11:838-874. 23847220
McMahon, B.; Stein, B. L. Thrombotic and Bleeding Complications in Classical Myeloproliferative Neoplasms.Semin Thromb Hemost (2013) 39:101-111. 23264112; 10.1055/s-0032-1331153
Mehrotra, S.; Sharma, B.; Joshi, S.; Kroczynska, B.; Majchrzak, B.; Stein, B. L.; McMahon, B.; Altman, J. K.; Licht, J. D.; Baker, D. P.; Eklund, E. A.; Wickrema, A.; Verma, A.; Fish, E. N.; Platanias, L. C. Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors.J Biol Chem (2013) 288:23814-23822. 23814052; PMC3745328; 10.1074/jbc.M113.476192
Stein, B. L.; Saraf, S.; Sobol, U.; Halpern, A.; Shammo, J.; Rondelli, D.; Michaelis, L.; Odenike, O.; Rademaker, A.; Zakarija, A.; McMahon, B.; Spivak, J. L.; Moliterno, A. R. Age-related Differences in Disease Characteristics and Clinical Outcomes in Polycythemia Vera.Leuk Lymphoma (2013) 54:1989-1995. 23245211; 10.3109/10428194.2012.759656
Stein, B. L.; Tiu, R. V. Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms.J Interferon Cytokine Res (2013) 33:145-153. 23570380; 10.1089/jir.2012.0120
Zangari, M.; Fink, L.; Tolomelli, G.; Lee, J. C.; Stein, B. L.; Hickman, K.; Swierczek, S.; Kelley, T. W.; Berno, T.; Moliterno, A. R.; Spivak, J. L.; Gordeuk, V. R.; Prchal, J. T. Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?Blood Coagul Fibrinolysis (2013) 24:311-316. 23392352; PMC3796441; 10.1097/MBC.0b013e32835bfdb9
Cull, E.; Stein, B. L. Splenic infarction, warm autoimmune hemolytic anemia and antiphospholipid antibodies in a patient with infectious mononucleosis.Int J Hematol (2012) 95:573-576. 22407854; 10.1007/s12185-012-1047-4
Sharma, B.; Joshi, S.; Sassano, A.; Majchrzak, B.; Kaur, S.; Aggarwal, P.; Nabet, B.; Bulic, M.; Stein, B. L.; McMahon, B.; Baker, D. P.; Fukunaga, R.; Altman, J. K.; Licht, J. D.; Fish, E. N.; Platanias, L. C. Sprouty proteins are negative regulators of interferon (IFN)-signaling and IFN-inducible biological responses.J Biol Chem (2012) 287:42352-42360. 23074222; PMC3516778; 10.1074/jbc.M112.400721
Stein, B. L. Chronic Myeloid Leukemia and the Risk of Second Malignancy in Two Eras of Treatment.Leuk Lymphoma (2012) 53:1651-1653. 22360717; 10.3109/10428194.2012.668684
Stein, B. L. The anemia of inflammation.J Clin Rheumatol (2012) 18:437-442. 23211586; 10.1097/RHU.0b013e318278f553
Stein, B. L.; Crispino, J. D.; Moliterno, A. R. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.Curr Opin Oncol (2011) 23:609-616. 21993415; 10.1097/CCO.0b013e32834d1b22
Stein, B. L.; Rademaker, A.; Spivak, J. L.; Moliterno, A. R. Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms.Thrombosis (2011) 2011:874146. 22084670; PMC3200304; 10.1155/2011/874146
Stein, B. L.; Smith, B. D. Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Leuk Res (2011) 35:1161-1163. 21782241; 10.1016/j.leukres.2011.06.026
Stein, B. L.; Williams, D. M.; O'Keefe, C.; Rogers, O.; Ingersoll, R. G.; Spivak, J. L.; Verma, A.; Maciejewski, J. P.; McDevitt, M. A.; Moliterno, A. R. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.Haematologica (2011) 96:1462-1469. 21712540; PMC3186307; 10.3324/haematol.2011.045591
Stein, B. L.; Williams, D. M.; Rogers, O.; Isaacs, M. A.; Spivak, J. L.; Moliterno, A. R. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.Exp Hematol (2011) 39:95-101. 20888389; PMC3004981; 10.1016/j.exphem.2010.09.008
Kalyani, R. R.; Stein, B.; Valiyil, R.; Manno, R.; Maynard, J. W.; Crews, D. C. Vitamin D treatment for the prevention of falls in older adults: systematic review and meta-analysis.J Am Geriatr Soc (2010) 58:1299-1310. 20579169; PMC3125705; 10.1111/j.1532-5415.2010.02949.x
Laughlin, T. S.; Moliterno, A. R.; Stein, B. L.; Rothberg, P. G. Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing.J Mol Diagn (2010) 12:278-282. 20203004; PMC2860462; 10.2353/jmoldx.2010.090177
Stein, B. L.; Moliterno, A. R. Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation.JAMA (2010) 303:2513-2518. 20571018; 10.1001/jama.2010.853

The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.


Co-Authors (9):

Similar Investigators (2):

Investigators you have not published with but by MeSH terms have significant overlap with your research

Keywords (MeSH):


Last updated from PubMed on Wednesday, April 23, 2014